Ehsan Hejazi1, Maryam Tavakoli2, Mahmood Jeddi-Tehrani3, Masoud Kimiagar1, Jalal Hejazi4, Mohammad Houshyari5, Zohre Amiri6, Hale Edalatkhah7, Javad Nasrollahzadeh1, Farah Idali2. 1. a Department of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology , Shahid Beheshti University of Medical Sciences , Tehran , Iran. 2. b Reproductive Immunology Research Center, Avicenna Research Institute , ACECR , Tehran , Iran. 3. c Monoclonal Antibody Research Center, Avicenna Research Institute , ACECR , Tehran , Iran. 4. d Department of Biochemistry and Nutrition, Faculty of Medicine , Zanjan University of Medical Sciences , Zanjan , Iran. 5. e Department of Radiation Oncology, Shohada Tajrish Hospital , Shahid Beheshti University of Medical Sciences , Tehran , Iran. 6. f Department of Basic Sciences and Cellular and Molecular Nutrition, School of Nutrition Sciences and Food Technology , Shahid Beheshti University of Medical Sciences , Tehran , Iran. 7. g Reproductive Biotechnology Research Center, Avicenna Research Institute , ACECR , Tehran , Iran.
Abstract
BACKGROUND: One major concern in the treatment of cancer patients during chemotherapy is drug resistance. Here we investigated the effects of soy isoflavone extracts alone or in combination with Docetaxel on the drug resistance, angiogenesis, apoptosis, and tumor volume in mouse 4T1 breast tumor model. METHODS: Sixty female BALB/c mice were randomly divided into 4 groups: control, dietary soy isoflavone extract [Iso, 100 mg/kg diet (0.01%)], Docetaxel (10 mg/kg) injection, and the combination of dietary soy isoflavone extract and intravenous Docetaxel injection (Docetaxel + Iso). One week after the third injection, the breast tumors of eight mice from each group were excised to analyze NF-κBp65' vascular endothelial growth factor receptor-2 (VEGFR2) and Pgp gene and protein expressions and the other seven mice were monitored for survival rate analysis until they died. RESULTS: NF-κBp65 gene and protein expressions were significantly lower in the Docetaxel + Iso group in comparison with that of the Docetaxel group. VEGFR2 protein expression in the Docetaxel + Iso and Iso groups was significantly lower than that of the Docetaxel group. CONCLUSION: These findings may indicate that the combined use of isoflavone extracts together with chemotherapeutic agents has more efficient anti-carcinogenic effects than their individual use.
BACKGROUND: One major concern in the treatment of cancerpatients during chemotherapy is drug resistance. Here we investigated the effects of soy isoflavone extracts alone or in combination with Docetaxel on the drug resistance, angiogenesis, apoptosis, and tumor volume in mouse 4T1 breast tumor model. METHODS: Sixty female BALB/c mice were randomly divided into 4 groups: control, dietary soy isoflavone extract [Iso, 100 mg/kg diet (0.01%)], Docetaxel (10 mg/kg) injection, and the combination of dietary soy isoflavone extract and intravenous Docetaxel injection (Docetaxel + Iso). One week after the third injection, the breast tumors of eight mice from each group were excised to analyze NF-κBp65' vascular endothelial growth factor receptor-2 (VEGFR2) and Pgp gene and protein expressions and the other seven mice were monitored for survival rate analysis until they died. RESULTS: NF-κBp65 gene and protein expressions were significantly lower in the Docetaxel + Iso group in comparison with that of the Docetaxel group. VEGFR2 protein expression in the Docetaxel + Iso and Iso groups was significantly lower than that of the Docetaxel group. CONCLUSION: These findings may indicate that the combined use of isoflavone extracts together with chemotherapeutic agents has more efficient anti-carcinogenic effects than their individual use.